BMJ Open · 2013 · 22 citations · 22 references
MedicineOncologyPediatricsChemotherapyPediatric CardiologyPediatric OncologyAnthracycline CardiotoxicityBaseline Cardiac EvaluationCancer Therapy-related CardiotoxicityPediatric Cardio-oncologyPediatric ChemotherapyPediatric EchocardiographyAcute Cardiac ToxicityAnthracycline-induced CardiotoxicityCardiotoxicityChronic Cardiac ToxicityDaunorubicin CardiotoxicityDoxorubicin CardiotoxicityPediatric Anthracycline CardiotoxicityPediatric Cancer Cardiotoxicity
OBJECTIVES: To identify anthracycline-induced acute (within 1 month) and early-onset chronic progressive (within 1 year) cardiotoxicity in children younger than 16 years of age with childhood malignancies at a tertiary care centre of Pakistan. DESIGN: Prospective cohort study. SETTING: Aga Khan University, Karachi, Pakistan. PARTICIPANTS: 110 children (aged 1 month-16 years). INTERVENTION: Anthracycline (doxorubicin and/or daunorubicin). OUTCOME MEASUREMENTS: All children who received anthracycline as chemotherapy and three echocardiographic evaluations (baseline, 1 month and 1 year) between July 2010 and June 2012 were prospectively analysed for cardiac dysfunction. Statistical analysis including systolic and diastolic functions at baseline, 1 month and 1 year was carried out by repeated measures analysis of variance. RESULTS: Mean age was 74±44 months and 75 (68.2%) were males. Acute lymphoblastic leukaemia was seen in 70 (64%) patients. Doxorubicin alone was used in 59 (54%) and combination therapy was used in 35 (32%). A cumulative dose of anthracycline <300 mg/m(2) was used in 95 (86%). Fifteen (14%) children developed cardiac dysfunction within a month and 28 (25%) children within a year. Of these 10/15 (66.6%) and 12/28 (43%) had isolated diastolic dysfunction, respectively, while 5/15 (33.3%) and 16/28 (57%) had combined systolic and diastolic dysfunction. Seven (6.4%) patients expired due to severe cardiac dysfunction. Eight of 59 (13.5%) children showed dose-related cardiotoxicity (p=<0.001). Cardiotoxicity was also high when the combination of doxorubicin and daunorubicin was used (p=0.004). CONCLUSIONS: Incidence of anthracycline-induced cardiotoxicity is high. Long-term follow-up is essential to diagnose its late manifestations.
22
Sherif F. Nagueh, Katherine J. Middleton, Helen A. Kopelen et al. · Journal of the American College of Cardiology · 1997 · 3K citations